company background image
DRUG logo

Bright Minds Biosciences NasdaqCM:DRUG Stock Report

Last Price

US$43.96

Market Cap

US$283.5m

7D

29.3%

1Y

2,201.6%

Updated

07 Feb, 2025

Data

Company Financials +

Bright Minds Biosciences Inc.

NasdaqCM:DRUG Stock Report

Market Cap: US$283.5m

DRUG Stock Overview

A biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. More details

DRUG fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Bright Minds Biosciences Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bright Minds Biosciences
Historical stock prices
Current Share PriceCA$43.96
52 Week HighCA$79.02
52 Week LowCA$0.93
Beta0.49
1 Month Change7.12%
3 Month Change-5.71%
1 Year Change2,201.57%
3 Year Change266.33%
5 Year Changen/a
Change since IPO62.81%

Recent News & Updates

Recent updates

Bright Minds says no material events fueled rally

Aug 18

Shareholder Returns

DRUGUS BiotechsUS Market
7D29.3%1.3%0.2%
1Y2,201.6%0.9%22.0%

Return vs Industry: DRUG exceeded the US Biotechs industry which returned 0.9% over the past year.

Return vs Market: DRUG exceeded the US Market which returned 22% over the past year.

Price Volatility

Is DRUG's price volatile compared to industry and market?
DRUG volatility
DRUG Average Weekly Movement12.6%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market18.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: DRUG's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: DRUG's weekly volatility has decreased from 207% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2017n/aIan McDonaldbrightmindsbio.com

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications.

Bright Minds Biosciences Inc. Fundamentals Summary

How do Bright Minds Biosciences's earnings and revenue compare to its market cap?
DRUG fundamental statistics
Market capUS$283.50m
Earnings (TTM)-US$1.96m
Revenue (TTM)n/a

0.0x

P/S Ratio

-154.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DRUG income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$2.80m
Earnings-CA$2.80m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did DRUG perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 00:28
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bright Minds Biosciences Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Charles DuncanCantor Fitzgerald & Co.
Sepehr ManochehryEight Capital